Avascular Necrosis Market
Report ID: SQMIG35I2807
Report ID: SQMIG35I2807
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2807 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
88
|Figures:
71
Global Avascular Necrosis Market size was valued at USD 4852.50 Million in 2024 and is poised to grow from USD 5193.15 Million in 2025 to USD 8985.40 Million by 2033, growing at a CAGR of 7.02% during the forecast period (2026-2033).
The main factor influencing the avascular necrosis (AVN) market trends is a rise in the frequency of osteonecrosis among aging patients and those using steroids. Older adults tend to have higher levels of comorbidities (other illnesses or diseases) that are known to speed up the deterioration of the joints. The AVN Market consists of diagnostics, surgical and pharmaceutical treatments, and rehabilitation pathways. It is important that the avascular necrosis (AVN) market develop into an effective treatment modality because if AVN remains untreated, the joint will collapse and thus create a large financial and quality of life burden on society. Over the past 20 years, there has been a change in the management of AVN from a symptom-based approach to an early imaging approach with methods of preserving the joint. Examples of this change are the adoption of MRI protocols for the early diagnosis of AVN, as well as core decompression plus biologics used together.
An example of technological advancements will contribute to the global AVN market growth is the increase in the number of new AVN diagnosis and treatments due to integration of technology into AVN care. As more asymptomatic AVN cases are being identified with MRI technology and algorithms for risk stratification, there has been and will continue to be an increase in the demand for joint preserving interventions (core decompression with stem cells) prior to collapse. Therefore, the commercial acceptance of biological agents that enhance the clinical use of biologics will add markets for cell-based therapies and scaffold constructs. Improvements in minimally invasive implants; along with the expanded reimbursement for early interventions will expand the criteria for patients to receive care and to increase the number of access points to AVN treatment.
How is AI Improving Diagnosis and Treatment Planning in the Avascular Necrosis Market?
Using predictable decision support combined with advanced imaging systems has allowed for great advancements in the diagnosis & planning of treatment for avascular necrosis market share. There are three main components of this process including: The automated interpretation of CT & MRI scans which identifies minor changes in bones that may be seen in their early stages, the utilization of machine learning models to analyze the projected progression of avascular necrosis & help a physician determine which joint-preserving alternatives are viable, and the use of computer-assisted surgical planning in which patient information collected from CT or MRI is converted to a unique, individual surgical plan for each patient. Both the current state of advanced imaging technologies for avascular necrosis combine clinical pilot studies with currently validated research models to provide augmented workflows for radiologists & orthopedic surgeons while decreasing uncertainty surrounding the diagnosis of avascular necrosis. The marketplace for AI in diagnosing & treating avascular necrosis is ripe for growth; many vendors are transitioning their clinically validated proof-of-concept products into standard of care products with the use of AI tools & algorithms becoming more common in the provision of routine care of musculoskeletal disorders.
In February 2026, Osteopore announced a grant funded collaboration with Tan Tock Seng Hospital (TTSH) to create a 3D-printed hip implant for patients with avascular necrosis. The combination of this 3D-printed implant with AI-driven imaging techniques can streamline the process of creating an individual patient-specific design, facilitate pre-surgical decision making & encourage the wider application of this imaging technique by improving efficiency & surgeon confidence in their surgical decision making.
Market snapshot - (2026-2033)
Global Market Size
USD 4852.5 Million
Largest Segment
Surgical
Fastest Growth
Non-Surgical
Growth Rate
7.02% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global avascular necrosis market is segmented by treatment type, stage, end-user and region. Based on treatment type, the market is segmented into surgical and non-surgical. Based on stage, the market is segmented into early stage (I-II) and late stage (III-IV). Based on end-user, the market is segmented into hospitals, orthopedic clinics and rehabilitation centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The surgical leads due to their providing definitive mechanical solutions for treatment of joint collapse and advanced joint disease, resulting in clinician preference and manufacturer investment. Surgical interventions restore function via debridement or joint replacement and attract capital for innovation in implant design, and they integrate into established hospital workflows thereby creating a stable revenue stream. The clinical predictability of using an operative approach is a driver for guideline development and training for specialists, consolidating procurement and establishing long-term trends of demand for surgical technologies/services.
However, non-surgical is witnessing rapid growth as minimally invasive therapies, biologic injectables, and pharmacologic strategies gain clinician and patient acceptance. Better early diagnosis and preference for conservative care attract investment in regenerative treatments, expanding outpatient management and creating opportunities for new products and service models that drive future market expansion.
The hospital market leads because they represent the center for complex care pathways and house the multidisciplinary specialists necessary to provide advanced care for a patient with avascular necrosis. Hospitals provide comprehensive imaging, operating rooms, and perioperative support that enable the implementation of high-acuity surgical procedures as well as execution of clinical trials, thereby attracting device companies and skilled surgeons. Hospitals have strong negotiating power due to their purchasing volume, existing payer relationships, and ability to act as referral centers, thereby accelerating their adoption of complex therapy and creating sustained demand that drives investment priorities in the avascular necrosis market.
However, orthopedic clinics are emerging as the key growth area due to focused procedural expertise and faster adoption of outpatient joint preserving techniques. Streamlined pathways, patient convenience, and collaboration with device innovators accelerate uptake of minimally invasive and regenerative options, expanding ambulatory care models and opening opportunities for manufacturers and providers.
To get detailed segments analysis, Request a Free Sample Report
The North American market benefits from a strong mature health system that allows for quick translation of clinical innovations into practice. Clinical research networks, specialty care centres, integrated care pathways all help with earlier diagnosis and multi-disciplinary management that drive demand for advanced therapeutics and devices. A favourable reimbursement and health insurance payment environment, a high level of private investment, and a business-friendly regulatory environment all support the commercial development and marketing of new medical products. The high degree of clinician expertise, established distribution networks, and collaboration between universities and corporate partners also contribute to the strength of the North America market. Patient education/advocacy contributes to timely referrals to specialists, while the regulatory process provides many clear pathways for access to new technologies and continues the introduction of new products into North America. In addition, there are many centres of excellence throughout North America that serve to attract providers from around the world and assist in the widespread adoption of best practice behaviours throughout North America.
Avascular necrosis market forecast in United States is characterized by concentrated specialist centres, advanced diagnostic capabilities, and a strong presence of implant and biologics manufacturers that accelerate innovation uptake. Integrated care pathways, established reimbursement frameworks, and experienced orthopedic surgeon networks support rapid clinical adoption. Active collaboration among academic institutions, industry sponsors, and specialist clinics enhances access to novel interventions and consolidates market leadership within the country, while supporting consistent clinical quality.
Avascular necrosis market outlook in Canada is shaped by regional centres of excellence and coordinated referral pathways that underpin patient management. Emphasis on multidisciplinary care and cautious adoption of advanced therapeutics supports integration of new treatments. Partnerships between academic hospitals and industry enable clinical evaluation and technology transfer. Policy frameworks and payer deliberations influence access, while telemedicine and outreach initiatives extend specialist reach to dispersed populations and reinforce consistent care delivery.
The overall expansion of Europe is driven by several coinciding factors that enable rapid adoption of new treatment modalities across many of the world's major healthcare systems. In many core markets, strong clinical infrastructures are already trackable for early diagnosis and a strong referral source to specialist opinions. The harmonization of regulatory pathways and creating cooperative networks, or consortiums, of academic centers with industry also support the ability to perform multicenter evaluations. The development of collaborative, cross-border relationships between academic institutions, clinical education targeted at physicians, and an increasing number of strategic investments by both global and regional companies will continue to bolster Europe as a highly energetic and increasingly significant player in the global marketplace. The ability to manufacture locally combined with a long tradition of developing clinical practice guidelines will facilitate the rapid adoption of new therapies, while specialized training programs and patient support activities will continue to enhance long-term care coordination and continuity of treatment between different healthcare organizations.
Avascular necrosis market regional outlook in Germany benefits from a network of specialized orthopedic centres and a mature medical device manufacturing base that supports clinical adoption. Strong hospital infrastructure, clinical research programmes, and established professional societies thereby encourage guideline driven practice. Collaborative ecosystems linking industry with academic hospitals enable clinical evaluation and product refinement. Reimbursement pathways and surgeon expertise sustain uptake of advanced interventions and consolidate Germany role as a market leader.
Avascular necrosis market regional forecast in United Kingdom is driven by strong investment in orthopedic innovation and evolving care models that emphasize early intervention. Specialist centres and progressive clinical networks promote uptake of novel therapeutics and devices. Collaborations among academic groups, private providers, and industry accelerate translational activity. Targeted training and pilot programmes enable swift clinical integration, expanding access to advanced treatment options across both hospital and community care pathways and initiatives.
Avascular necrosis market analysis in France is evolving as clinical interest grows and policy frameworks adapt to support treatment pathways. Strong academic hospitals and specialty clinics generate evidence and foster multidisciplinary care approaches. Centralised evaluation processes and active engagement between industry and clinical stakeholders guide introduction of new technologies. Greater emphasis on patient pathways, rehabilitation, and regional centres of expertise is strengthening capacity to adopt advanced interventions and enhance care continuity.
The Asia Pacific change will happen from a mix of growing clinical capabilities, investing in orthopedics and medtech activity as well as growing those activities within their own countries. Many countries such as Japan and South Korea have a solid foundation for clinical expertise and hospital networks that will support the introduction of advanced diagnostic systems and surgical techniques. There are still many regulatory pathways in the region that are geared toward improving the ability to innovate, however, the creation of collaborative agreements between local developers and international manufacturers is speeding up the process of technology transfer. Improving training for physicians, providing a wider range of imaging and special services and increasing awareness among primary care physicians should lead to better detection and control of diseases in the early stages. Establishing strategic partnerships between public and private entities, in addition to organizing clinical trials and creating centres of excellence in the region, is establishing a more competitive and sustainable base for the Asia Pacific region within the global marketplace. The use of digital health technologies (e.g. telemedicine and telemonitoring) helps support follow-up care and multiple disciplines working together across distances. New innovation hubs combined with greater support and investment from local companies in the development of implants will continue to grow the capacity of the Asia Pacific region and development/partnerships within this area.
Avascular necrosis industry in Japan is supported by advanced imaging capabilities, high levels of specialist clinical expertise, and a strong domestic medical technology sector that drives innovation. Concentrated centres of excellence facilitate surgical procedures and multidisciplinary management approaches. Regulatory and reimbursement frameworks are nationally oriented toward evaluated clinical benefit, encouraging uptake of new devices. Strategic partnerships with international developers and focused clinician training programmes enhance clinical adoption and technology diffusion.
Avascular necrosis industry analysis in South Korea features swift clinical adoption of advanced surgical techniques and a dynamic medtech industry that supports development. Tertiary hospitals and specialist centres provide focused expertise and enable case management. Collaboration between domestic manufacturers and international partners facilitates technology transfer and clinical evaluation. Emphasis on clinician training, digital integration in care pathways, and targeted research initiatives strengthens capacity to introduce innovative interventions and expand specialist access.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advances In Surgical Techniques
Growing Demand For Regenerative Therapies
High Treatment And Device Costs
Limited Clinical Evidence And Awareness
Request Free Customization of this report to help us to meet your business objectives.
Competition in the global avascular necrosis market is shaped by large orthopedics incumbents and fast-moving orthobiologics and surgical tech startups. Competitive drivers include M&A and distribution deals to secure implant and tissue supply, partnerships with tissue processors, and clinical-stage platform innovation such as targeted protein delivery and next generation bone grafts. Recent, concrete moves include strategic acquisitions by large device firms, partnership rollouts by orthobiologics firms, and clinical progress at targeted regenerative startups.
Top Player’s Company Profile
Recent Developments in the Avascular Necrosis Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the global avascular necrosis market is poised for steady growth, with one key driver being the rising incidence of osteonecrosis linked to aging populations and expanded corticosteroid use and one restraint being high treatment and device costs that limit uptake. The dominating region is North America, supported by mature clinical networks and favorable reimbursement, and the dominating segment is surgical treatments which continue to command clinician preference for advanced disease. A second driver is technological integration including advanced imaging, AI-supported diagnosis and growing regenerative and biologic adjuncts that enable earlier, joint-preserving interventions and broaden commercial opportunities.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 4852.5 Million |
| Market size value in 2033 | USD 8985.4 Million |
| Growth Rate | 7.02% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Avascular Necrosis Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Avascular Necrosis Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Avascular Necrosis Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Avascular Necrosis Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Avascular Necrosis Market size was valued at USD 4852.5 Million in 2024 and is poised to grow from USD 5193.15 Million in 2025 to USD 8985.4 Million by 2033, growing at a CAGR of 7.02% during the forecast period (2026-2033).
Competition in the global avascular necrosis market is shaped by large orthopedics incumbents and fast-moving orthobiologics and surgical tech startups. Competitive drivers include M&A and distribution deals to secure implant and tissue supply, partnerships with tissue processors, and clinical-stage platform innovation such as targeted protein delivery and next generation bone grafts. Recent, concrete moves include strategic acquisitions by large device firms, partnership rollouts by orthobiologics firms, and clinical progress at targeted regenerative startups. 'Zimmer Biomet', 'Stryker Corporation', 'DePuy Synthes (J&J)', 'Smith & Nephew', 'Wright Medical Group', 'Exactech Inc.', 'Pfizer Inc.', 'Novartis AG', 'Amgen Inc.', 'Eli Lilly and Company', 'Medtronic', 'Bioventus LLC', 'Arthrex Inc.', 'Conformis Inc.', 'Merete Medical GmbH'
Advances in surgical techniques have improved procedural success and patient outcomes for avascular necrosis, increasing clinician confidence and expanding the pool of patients considered suitable for intervention. Greater predictability of surgical approaches encourages hospitals and specialist centers to adopt these procedures and invest in associated devices and training. As surgeons refine minimally invasive and joint preserving methods, referral patterns shift toward earlier interventional management, supporting demand for implants and regenerative products and fostering greater integration of care pathways that sustain broader market uptake.
Biologics And Regenerative Therapies: Advances in biologic and regenerative therapies are driving interest in joint preservation strategies for avascular necrosis. Developers and clinicians are exploring cell based implants, growth factor delivery, scaffold materials to promote bone regeneration and delay joint replacement. This trend is encouraging collaboration between orthopedics and biotechnology firms, stimulating clinical research and diversification. Payers and providers are increasingly focused on long term functional outcomes, which supports adoption of biologic solutions that align with patient quality of life objectives and reduced interventions.
Why does North America Dominate the Global Avascular Necrosis Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
